Oruka Therapeutics, Inc. ORKA Reclassification Of The Paruka Warrant From Liability To Equity
Reclassification Of The Paruka Warrant From Liability To Equity at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept orka:ReclassificationOfTheParukaWarrantFromLiabilityToEquity.
The official record: Oruka Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Oruka Therapeutics, Inc.'s reclassification of the paruka warrant from liability to equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Oruka Therapeutics, Inc.'s reclassification of the paruka warrant from liability to equity?
- Oruka Therapeutics, Inc. (ORKA) reported reclassification of the paruka warrant from liability to equity of $2.52M in Q4 2025.
- How has Oruka Therapeutics, Inc.'s reclassification of the paruka warrant from liability to equity changed year-over-year?
- Oruka Therapeutics, Inc.'s reclassification of the paruka warrant from liability to equity decreased by 75.7% year-over-year, from $10.36M to $2.52M.
- What does reclassification of the paruka warrant from liability to equity mean?
- Reflects the accounting adjustment where warrant obligations are moved from the liability section to the equity section of the balance sheet. This reclassification typically occurs when the warrants meet specific criteria for equity classification, reducing volatility in the income statement. It signals a change in the nature of the company's financial commitments to warrant holders.